Airborne and potentially deadly, the virus that causes COVID-19 can only be studied safely under high-level biosafety conditions. Scientists handling the infectious virus must wear full-body biohazard suits with pressurized respirators, and work inside laboratories with multiple containment levels and specialized ventilation systems. While necessary to protect laboratory workers, these safety…
At around 30.5 percent, breast cancer is the most common cancer among women in countries of the industrialized world. The number of cases has doubled since the 1980s: about 69,000 times a year women are diagnosed with breast cancer. Triple-negative breast cancer is a particularly aggressive form of breast cancer. As important receptors are missing here, treatment options and prognosis for such…
EKF Diagnostics, the global in vitro diagnostics company, announces that it has added a novel viral transport media for the safe sample handling and testing of multiple infectious diseases from a single swab to its product range.
The human species maintains symbiotic relationships with a multitude of microbial organisms that colonise the inside as well as the surface of the body. Scientists, for a long time, underestimated the significance of these organisms for humans.
Nanoelectronics and digital technologies R&D and innovation hub Imec recently received NASA funding to test a new technology in a gravity-free environment. Eventually, this will enable astronauts to perform blood tests to monitor their health. We discussed the project and technology with Nicolas Vergauwe, CEO of miDiagnostics, the Leuven firm that developed the diagnostic device, and Susana B…
Following success of telepathology in the eastern region of Quebec, the service is set to be further expanded across its remote areas. There are also moves towards a fully digital service at some sites, to introduce tele-autopsy into remote regions and extend the geographical coverage further across the region. The latest developments were outlined at the Digital Pathology and AI Congress in…
To investigate rare diseases, applying image-based analytics approaches, including the use of deep learning convolutional neural networks (DL-CNNs), can be a major challenge due to great difficulties in acquiring sufficient numbers of cases and associated digital image sets from the small cohorts typically available. To realise algorithms that are both effective and generalisable, conventional…
Public Health England, in partnership with the University of Oxford, recently conducted a head-to-head evaluation of four commercial immunoassay tests available in the UK and used for the detection of SARS-CoV-2 antibodies.
Hamamatsu Photonics invites you to join us for a panel discussion with pathologist Matthew Hanna, MD and IT Manager Nikolas Stathonikos on Thursday, 9 July at 17:00 CET. In this rapidly evolving healthcare landscape triggered by COVID-19, pathology, and remote diagnosis have been elevated to critical topics. These two experts, representing both the clinical and information technology areas, will…
Major weaknesses exist in the evidence base for COVID-19 antibody tests, finds a review of the latest research published by The BMJ. The evidence is particularly weak for point-of-care tests (performed directly with a patient, outside of a laboratory) and does not support their continued use, say the researchers. Serological tests to detect antibodies against COVID-19 could improve diagnosis and…
Beckman Coulter announced that its Access SARS-CoV-2 IgG assay has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA). Beckman Coulter has already shipped tests to more than 400 hospitals, clinics and diagnostics laboratories in the U.S., and has begun distribution of the new antibody test globally to countries that accept the FDA EUA and CE Mark. The…
A group of senior clinical academics and physicians are concerned about the rapid roll out of COVID-19 antibody testing in England and are publicly questioning how good the tests are - or even what they mean. In a letter to The BMJ, they argue that there is currently no valid clinical reason for large scale testing, test performance has not yet been adequately assessed, and testing risks…
To develop and manufacture COVID-19 test kits in massive quantities was not part of their 2020 business plans. Yet, as the epidemic evolved into a global pandemic, the urgent need for diagnostic and antibody SARS-CoV-2 test kits triggered an unprecedented scramble among medical manufacturers.
In many areas of our daily life, plastic is seen in a negative light. However, the ongoing SARS CoV-2 pandemic has profoundly changed our society with intensive efforts being made to find a way out of the crisis.
A Danish pipetting robot is automating Covid testing processes in hospitals around Europe. The robot, called flowbot ONE, significantly reduces the time it takes for laboratories to produce results for patients to tell them whether they are infected with Covid-19.
The Norfolk and Norwich University Hospital (NNUH) has taken the first steps towards establishing a digital histopathology service, which will help to improve cancer care. New systems are being introduced to embrace new technology to track specimens, digitise slides and enable clinicians to analyse and report cases digitally on computers.
A new diagnostic test can detect the RNA of SARS-CoV-2, the virus that causes COVID-19, in urine, blood, saliva or mouth swab samples in just 30 to 45 minutes, according to a new study in the open-access journal PLOS ONE by Laura Lamb of the Beaumont Health System, Michigan, USA, and colleagues.
The oncogenic herpesvirus (HHV8 or KSHV) causes a cancer known as Kaposi’s Sarcoma. An international team of scientists led by the University of Helsinki has discovered key factors that control the genome maintenance and replication of a virus responsible for lymphatic vascular cancer. Kaposi Sarcoma (KS) is the most common cancer among Aids patients and it is often seen in sub Saharan and…
Scientists in the life sciences can now benefit from upgrades to a suite of analytical software solutions with new features designed to enhance productivity, confidence and accuracy in numerous fields, including proteomics, food safety and biotherapeutic drug development. The latest suite of software strengthens laboratory workflows across a range of applications through expanded capabilities,…
Researchers at the Francis Crick Institute and Charité – Universitätsmedizin Berlin have identified 27 protein biomarkers that could be used to predict whether a patient with COVID-19 is likely to become severely ill with the disease. People infected with SARS-CoV-2, the virus which causes COVID-19, respond differently. Some do not develop any symptoms, some need to be hospitalised and, for…
What makes tumor cells turn murderous? The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is investigating the mechanisms of metastasis formation – and searching for approaches for new treatments in the fight against cancer. Among other things, the research team at Fraunhofer ITEM has developed a method that enables them to analyze entire lymph nodes.
One of the most effective ways to protect yourself against needle-stick injuries (NSI) is to use safety products in your everyday work. In this area, Greiner Bio-One can offer you a comprehensive portfolio for a variety of requirements.
Siemens Healthineers announced today that it is now shipping worldwide its laboratory-based total antibody test1 to detect the presence of SARS-CoV-2 IgM and IgG antibodies in blood.
Tissue biopsy slides stained using hematoxylin and eosin (H&E) dyes are a cornerstone of histopathology, especially for pathologists needing to diagnose and determine the stage of cancers. A research team led by MIT scientists at the Media Lab, in collaboration with clinicians at Stanford University School of Medicine and Harvard Medical School, now shows that digital scans of these biopsy…
Researchers at Hokkaido University have succeeded in detecting anti-avian influenza virus antibody in blood serum within 20 minutes, using a portable analyzer they have developed to conduct rapid on-site bio tests. If a suitable reagent is developed, this technology could be used to detect antibodies against SARS-CoV-2, the causative virus of COVID-19.